Myeloid suppressor cell-associated immune dysfunction in CSA1M fibrosarcoma tumor-bearing mice

Cancer Science

Volumn 98, Issue 6, 2007, Pages 882-889

  Zhou, Ru ^a   He, Pei Lan ^a   Ren, Yong Xin ^a   Wang, Wen Hai ^b   Zhou, Rong Yao ^b   Wan, Hua ^b   Ono, Shiro ^c   Fujiwara, Hiromi ^c   Zuo, Jian Ping ^a,b  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE; CD4 ANTIGEN; CD8 ANTIGEN; CONCANAVALIN A; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERFERON REGULATORY FACTOR 1; INTERLEUKIN 10; INTERLEUKIN 4; LIPOPOLYSACCHARIDE; MESSENGER RNA; NITRIC OXIDE; STAT1 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; BONE MARROW CELL; CANCER STAGING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COUNT; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DELAYED HYPERSENSITIVITY; ENZYME ACTIVITY; EXPERIMENTAL MOUSE; FIBROSARCOMA; IMMUNE DEFICIENCY; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL; SPLENOMEGALY; SUPPRESSOR CELL;

ANIMALS; ARGINASE; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CONCANAVALIN A; CYTOKINES; FIBROSARCOMA; IMMUNE TOLERANCE; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED BALB C; MYELOID PROGENITOR CELLS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; SPLEEN; SPLENOMEGALY; T-LYMPHOCYTES, HELPER-INDUCER; T-LYMPHOCYTES, REGULATORY;

EID: 34247859288     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00465.x     Document Type: Article

References (28)

1. Nestle FO, Alijagic S, Gilliet M et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4: 328-32.
2. Almand B, Clark JI, Nikitina E et al. Increased production of immature myeloid cells in cancer patients: A mechanism of immunosuppression in cancer. J Immunol 2001; 166: 678-89.
3. Bronte V, Apolloni E, Cabrelle A et al. Identification of a CD11b(+)/ Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. Blood 2000; 96: 3838-46.
4. Gabrilovich DI, Velders MP, Sotomayor EM, Kast WM. Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J Immunol 2001; 166: 5398-406.
5. Serafini P, De Santo C, Marigo I et al. Derangement of immune responses by myeloid suppressor cells. Cancer Immunol Immunother 2004; 53: 64-72.
6. Staveley-O'Carroll K, Sotomayor E, Montgomery J et al. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. Proc Natl Acad Sci USA 1998; 95: 1178-83.
7. Ochoa JB, Strange J, Kearney P, Gellin G, Endean E, Fitzpatrick E. Effects of 1-arginine on the proliferation of T lymphocyte subpopulations. JPEN J Parenter Enteral Nutr 2001; 25: 23-9.
8. Bronte V, Serafini P, De Santo C et al. IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J Immunol 2003; 170: 270-8.
9. Wu G, Morris SM Jr. Arginine metabolism: Nitric oxide and beyond. Biochem J 1998; 336: 1-17.
10. Liu Y, Van Ginderachter JA, Brys L, De Baetselier P, Raes G, Geldhof AB. Nitric oxide-independent CTL suppression during tumor progression: association with arginase-producing (M2) myeloid cells. J Immunol 2003; 170: 5064-74.
11. Zou JP, Shimizu J, Ikegame K et al. Tumor-bearing mice exhibit a progressive increase in tumor antigen-presenting cell function and a reciprocal decrease in tumor antigen-responsive CD4+ T cell activity. J Immunol 1992; 148: 648-55.
12. Yoshida TO, Haraguchi S, Miyamoto H, Matsuo T. Recognition of RSV-induced tumor cells in syngeneic mice and semisyngeneic reciprocal hybrid mice. Gann Monogr Cancer Res 1979; 23: 201-12.
13. Yang YF, Mukai T, Gao P et al. A non-peptide CCR5 antagonist inhibits collagen-induced arthritis by modulating T cell migration without affecting anti-collagen T cell responses. Eur J Immunol 2002; 32: 2124-32.
14. Zhou R, Zhang F, He PL et al. (5R) -5-hydroxytriptolide (LLDT-8), a novel triptolide analog mediates immunosuppressive effects in vitro and in vivo. Int Immunopharmacol 2005; 5: 1895-903.
15. Zhou R, Zheng SX, Tang W et al. Inhibition of Inducible Nitric-Oxide Synthase Expression by (5R)-5-hydroxytriptolide (LLDT-8) in Interferon- {gamma} and Bacterial Lipopolysaccharide Stimulated Macrophages. J Pharmacol Exp Ther 2006; 316: 121-8.
16. Corraliza IM, Campo ML, Soler G, Modolell M. Determination of arginase activity in macrophages: A micromethod. J Immunol Meth 1994; 174: 231-5.
17. Zou JP, Nagata T, Yamamoto N, Ono S, Fujiwara H, Hamaoka T. Recovery of antitumor CD4+ T cell responsiveness, suppressed in the tumor-bearing state, by release from tumor burden. J Cancer Res Clin Oncol 1994; 120: 279-85.
18. Fujiwara H, Hamaoka T. Regulatory mechanisms of antitumor T cell responses in the tumor-bearing state. Immunol Res 1995; 14: 271-91.
19. Pisa P, Halapi E, Pisa EK et al. Selective expression of interleukin 10, interferon gamma, and granulocyte-macrophage colony-stimulating factor in ovarian cancer biopsies. Proc Natl Acad Sci USA 1992; 89: 7708-12.
20. De Smedt T, Van Mechelen M, De Becker G, Urbain J, Leo O, Moser M. Effect of interleukin-10 on dendritic cell maturation and function. Eur J Immunol 1997; 27: 1229-35.
21. Salazar-Onfray F, Charo J, Petersson M et al. Down-regulation of the expression and function of the transporter associated with antigen processing in murine tumor cell lines expressing IL-10. J Immunol 1997; 159: 3195-202.
22. Mills CD. Macrophage arginine metabolism to ornithine/urea or nitric oxide/citrulline: A life or death issue. Crit Rev Immunol 2001; 21: 399-425.
23. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003; 3: 23-35.
24. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: Tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002; 23: 549-55.
25. Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol 2000; 164: 6166-73.
26. Yu WG, Yamamoto N, Takenaka H et al. Molecular mechanisms underlying IFN-gamma-mediated tumor growth inhibition induced during tumor immunotherapy with rIL-12. Int Immunol 1996; 8: 855-65.
27. Sinha P, Clements VK, Miller S, Ostrand-Rosenberg S. Tumor immunity: A balancing act between T cell activation, macrophage activation and tumor-induced immune suppression. Cancer Immunol Immunother 2005; 54: 1137-42.
28. Mills CD, Shearer J, Evans R, Caldwell MD. Macrophage arginine metabolism and the inhibition or stimulation of cancer. J Immunol 1992; 149: 2709-14.